Daniel Rupp
Overview
Explore the profile of Daniel Rupp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pollmann J, Gotz J, Rupp D, Strauss O, Granzin M, Grunvogel O, et al.
J Hepatol
. 2017 Nov;
68(3):421-430.
PMID: 29100993
Background & Aims: Natural killer (NK) cells are found at increased frequencies in patients with hepatitis C virus (HCV). NK cell activation has been shown to correlate with HCV clearance...
2.
Baumann S, Rupp D, Becher T, Behnes M, Sadick M, Borggrefe M, et al.
Coron Artery Dis
. 2017 Aug;
29(1):81-82.
PMID: 28799980
No abstract available.
3.
Levander S, Holmstrom F, Frelin L, Ahlen G, Rupp D, Long G, et al.
Gut
. 2017 Jun;
67(8):1525-1535.
PMID: 28646094
Objective: HCV is characterised by its ability to establish chronic infection in hepatocytes and to replicate in the presence of an inflammation. We mimicked this situation in vivo in immune-competent...
4.
Senis E, Mockenhaupt S, Rupp D, Bauer T, Paramasivam N, Knapp B, et al.
Nucleic Acids Res
. 2016 Sep;
45(1):e3.
PMID: 27614072
Successful RNAi applications depend on strategies allowing robust and persistent expression of minimal gene silencing triggers without perturbing endogenous gene expression. Here, we propose a novel avenue which is integration...
5.
Dietz J, Rupp D, Susser S, Vermehren J, Peiffer K, Filmann N, et al.
PLoS One
. 2016 Jun;
11(6):e0156731.
PMID: 27281344
Triple therapy of chronic hepatitis C virus (HCV) infection with boceprevir (BOC) or telaprevir (TVR) leads to virologic failure in many patients which is often associated with the selection of...
6.
Kalaghatgi P, Sikorski A, Knops E, Rupp D, Sierra S, Heger E, et al.
PLoS One
. 2016 May;
11(5):e0155869.
PMID: 27196673
The face of hepatitis C virus (HCV) therapy is changing dramatically. Direct-acting antiviral agents (DAAs) specifically targeting HCV proteins have been developed and entered clinical practice in 2011. However, despite...
7.
Mockenhaupt S, Grosse S, Rupp D, Bartenschlager R, Grimm D
Proc Natl Acad Sci U S A
. 2015 Jul;
112(30):E4007-16.
PMID: 26170322
Exogenous RNAi triggers such as shRNAs ideally exert their activities exclusively via the antisense strand that binds and silences designated target mRNAs. However, in principle, the sense strand also possesses...
8.
Poenisch M, Metz P, Blankenburg H, Ruggieri A, Lee J, Rupp D, et al.
PLoS Pathog
. 2015 Jan;
11(1):e1004573.
PMID: 25569684
Hepatitis C virus (HCV) is a major cause of chronic liver disease affecting around 130 million people worldwide. While great progress has been made to define the principle steps of...
9.
Irving W, Rupp D, McClure C, Than L, Titman A, Ball J, et al.
Antiviral Res
. 2014 Jul;
110:52-9.
PMID: 25057759
A new generation of drugs targeting the non-structural (NS) proteins of the Hepatitis C virus (HCV) will substantially increase treatment success rates, reducing global infections. Amongst the NS proteins, the...
10.
Rupp D, Bartenschlager R
Semin Liver Dis
. 2014 May;
34(1):9-21.
PMID: 24782254
Presently, interferon- (IFN-) containing treatment regimens are the standard of care for patients with hepatitis C virus (HCV) infections. Although this therapy eliminates the virus in a substantial proportion of...